Gardasil Shows Why Government Health Care is Dangerous

Gardasil gives various government agencies and their friends a pretext to get involved in a whole new area: the private lives of very young girls. Your girls.

American Thinker
October 23, 2009

By Duncan Maxwell Anderson

Gardasil has to be the perfect drug for the brave new world of ObamaCare, in a 1984 kind of way. Made by Merck & Co., it was approved in 2006 for use against venereal disease in young girls. Here’s why it’s so culturally suited for hope and change — and such a perfect example of why you don’t want the government in your medicine chest:
1) Gardasil has owed most of its success to the fact that government agencies have been subsidizing its sales, recommending its use, and even talking about requiring it.
2) Administered to girls as young as nine, it seems likely to help them grow up feeling ever so much safer about “safe sex.” They’ll be freer to rebel against bad old, religion-based morality, and more inclined to bond (as it were) with peers, school, the state and charismatic politicians who are always repeating themselves.
3) Best of all, it now appears that Gardasil doesn’t work.

Gardasil was promoted as the first vaccine against cancer, since it works against human papilloma virus (HPV), which is believed to instigate the growth of cancerous cells in a woman’s cervix. But since it was first hurriedly approved by the Food and Drug Administration, Gardasil has been dogged by criticism that it hasn’t been adequately tested, and by persistent reports of side effects, including deaths. So has a similar drug, Cervarix, made by GlaxoSmith-Kline.

As news of the risks has come out, the reply from Gardasil’s pharma-industry supporters has been to denounce “fear-mongering,” and to reiterate that the drug will reduce the cervical cancer rate in America. Alas, a presentation at a conference by one of Merck’s top researchers on October 2 appears to show otherwise. Here is a link to an article by Steven W. Mosher and Joan Robinson of the Population Research Institute (PRI), commenting on the talk by Merck consultant Dr. Diane Harper, who helped develop both Gardasil and Cervarix.

Dr. Harper has on several occasions criticized the rush to market of both HPV drugs. But her October 2 talk at the Fourth International Public Conference on Vaccination in Reston, Va., was framed as emphasizing the benefits of Gardasil. Nevertheless, according to PRI, her presentation openly stated that, 26 million vaccinations after its debut, Gardasil will have no effect on the rate of cervical cancer in the U.S. HPV, the infection that Gardasil can prevent, is rare, usually heals itself, and testing and treatment in the U.S. are very effective in keeping cervical cancer a rare event.


Comment from Leslie –

There are 69 excellent comments to this article on American Thinker – make sure that you do read them all.


Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.

Speak Your Mind